

## Company announcement no 3/2021

### Interim Report Q4 2020

EBITDA fixed herd prices (FHP) for Q4 2020 decreased to 486 kEUR (Q4 2019: 6,104 kEUR), corresponding to an EBITDA margin FHP of 2.2% (Q4 2019: 19.8%). The reduction from 2019 Q4 to 2020 Q4 is driven by reduction in sales prices 1.28 EUR to 0.92 EUR being 28% lower.

Sales prices in Q4 were 0.92 EUR/kg live weight down from 1.12 EUR/kg (Q3 2020). The price decrease from Q4 has been driven by ASF outbreak in Germany.

The outlook is highly uncertain with the ASF situation in China/Germany and a potential rebound of Coronavirus impacting supply chains.

Feed prices in Q4 were 232 EUR/T, 1% above Q1-Q3 2020 (compared to 240 EUR/T Q4 2019). A significant amount of grain is hedged until harvest 2021 either in storage or contract, reducing feed price fluctuations going forward.

The herd valuation in Q4 decreased by 4,121 mEUR (compared to 30.09.2020). Lower prices drove the decrease in EU and Lithuania and Russia followed partly.

Free cash flow was -748 kEUR in Q4 2020 (Q4 2019: -5.849 kEUR).

Net interest-bearing debt has last quarter increased from 64,0 mEUR to 87,4 mEUR driven by repurchase of 20% shares from (IFC 17,9 mEUR) due to put option medio December.

### Selected financial highlights and key ratios

EUR millions	Q4 2020	Q4 2019	2020	2019
Total revenue	22.471	30.900	101.754	110.540
EBITDA	-3.635	8.699	10.480	26.918
EBITDA margin	-16,2%	28,2%	10,3%	24,4%
EBITDA fixed herd price	486	6.104	19.744	22.829
EBITDA margin fixed herd price	2,2%	19,8%	19,4%	20,7%
Net income	-8.044	2.376	-7.761	10.979
Free cash flow	-748	-5.849	24.420	-807
Net interest-bearing debt	87.346	90.143	87.346	90.143

## Further information

Bondholders - Claus Baltersen, CEO phone +370 (685) 34 104

Media - Jytte Rosenmaj, Board Member phone +45 26 73 46 99

## Forward-looking statements

This interim report contains “forward-looking statements.” Undue reliance should not be placed on forward-looking statements because they relate to and depend on circumstances that may or may not occur in the future, and actual results may differ materially from those in forward-looking statements. Forward-looking statements include, without limitation, statements regarding our business, financial circumstances, strategy, results of operations, financing and other plans, objectives, assumptions, expectations, prospects, beliefs and other future events and prospects. We undertake no obligation and do not intend to publicly update or revise any of these forward-looking statements unless prescribed by law or by stock exchange regulation.

## Table of contents

REVIEW .....	4
Financial Highlights and Key Ratios.....	4
Management's Review .....	5
Development in segments in Q4 2020 .....	6
Statement by the Board and the Executive Management.....	8
FINANCIAL STATEMENT .....	9
Income Statement .....	9
Statement of comprehensive income .....	9
Assets .....	10
Liabilities and Equity.....	10
Cash Flow Statement .....	11
Statement of changes in equity .....	12
Notes.....	13
Quarterly Financial Highlights and Key Ratios.....	17

## Review

### Financial Highlights and Key Ratios

EUR '000	Q4 2020	Q4 2019	2020	2019
<b>Income statement</b>				
Revenue	22.471	30.900	101.754	110.540
EBITDA	-3.635	8.699	10.480	26.918
EBITDA fixed herd price	486	6.104	19.744	22.829
EBIT	-5.740	5.825	2.781	18.419
Financial items, net	-3.054	-1.437	-11.224	-4.803
Profit/(loss) for the period	-8.044	2.376	-7.761	10.979
<b>Cash flow</b>				
Operating activity	-2.065	-2.616	21.768	2.710
Investing activity	-1.466	-4.350	-4.217	-9.593
Financing activity	9.366	8.781	-5.996	-2.769
Free cash flow	-748	-5.849	24.420	-807
<b>Balance sheet</b>				
Non-current assets	97.353	115.024	97.353	115.024
Net working capital	11.079	32.075	11.079	32.075
Net operating assets	108.432	147.099	108.432	147.099
Total assets	146.369	200.082	146.369	200.082
Equity	29.867	67.348	29.868	67.348
Net interest bearing debt	87.346	90.143	87.346	90.143
<b>Key financials Group</b>				
EBITDA margin	-16,2%	28,2%	10,3%	24,4%
EBITDA margin - fixed herd prices	2,2%	19,8%	19,4%	20,7%
Cash conversion - fixed herd prices	-154%	-96%	124%	-4%
NIBD / EBITDA fixed price LTM	4,4	3,9	4,4	3,9
Equity ratio	20,4%	33,7%	20,4%	33,7%

## Management's Review

### Income statement

#### Revenue

The revenue for Q4 2020 was 22,471 kEUR (Q4 2019: 30,900 kEUR) down 27%. The lower sale is due to lower sales prices of 28% compared to Q4 2019, partly compensated with higher volume.

#### Value adjustment, biological assets

The herd valuation in Q4 decreased by 4,121 mEUR (compared to 30.09.2020). Lower prices drove the decrease in EU and Lithuania and Russia followed partly.

#### EBITDA fixed herd prices (FHP)

EBITDA fixed herd prices (FHP) for Q4 2020 decreased to 486 kEUR (Q4 2019: 6,104 kEUR), corresponding to an EBITDA margin FHP of 2.2% (Q4 2019: 19.8%). The reduction from 2019 Q4 to 2020 Q4 is driven by reduction in sales prices 1.28 EUR to 0.92 EUR being 28% lower.

Sales prices in Q4 were 0.92 EUR/kg live weight down from 1.12 EUR/kg (Q3 2020). The price decrease from Q4 has been driven by ASF outbreak in Germany.

Feed prices in Q4 were 232 EUR/T, 1% above Q1-Q3 2020 (compared to 240 EUR/T Q4 2019). A significant amount of grain is hedged until harvest 2021 either in storage or contract, reducing feed price fluctuations going forward.

#### Net financials

The net interest expenses for Q4 2020 increase 1,955 kEUR to 3,560 kEUR (Q4 2019: 1,605 kEUR). Interest in Q4 2020 is negatively impacted by re-financing bonds (extraordinary expensed rest cost of previous bond and premium paid to old bondholders 1,9 mEUR).

Foreign exchange adjustments in Q4 2020 was positive with 506 kEUR (Q4 2019 +167 kEUR), the foreign exchange adjustments are driven mainly by currency fluctuations in intercompany debt (405 kEUR Q4 2020) hence limited cash effect.

### Balance Sheet

At 31 September 2020, Idavang's balance sheet amounted to 146,369 kEUR (December 2019: 200,082 kEUR).

Equity on 31st December 2020 amounted to EUR 29.9m at an equity ratio of 20%.

Net interest-bearing debt has last quarter increased from 64,0 mEUR to 87,4 mEUR driven by repurchase of 20% shares from IFC 17,9 mEUR due to IFC utilizing the put option medio December.

The networking capital decreased to 11,079 kEUR (from 32,075 kEUR Q4 2019). The decrease of 20,996 kEUR is mainly due to 13,828 kEUR due to adverse price and exchange rate effect on the commercial herd and lower inventories due to higher hedge level with contracts (-3,404 kEUR).

### Cash flow

Cash flow from ordinary activities for Q4 2020 increased to -2,065 kEUR (Q4 2019: -2,616 kEUR). The increase of 551 kEUR consists of mainly of two factors, positive factor being improvement of net working capital of 0.3 mEUR (whereas 2019 Q4 was -8,0 mEUR) and negative factor being EBITDA FHP decreased with 5,618 kEUR.

### Events after the balance sheet date

- No events after the balance sheet date

## Development in segments in Q4 2020

### Lithuania

EUR '000	Q4 2020	Q4 2019	2020	2019
Revenue	12.314	19.327	60.551	65.052
Value adjustment, biological assets	-2.938	3.302	-11.270	7.894
Production costs	-13.843	-14.688	-53.098	-54.833
Administrative costs	-519	-368	-1.844	-1.904
Other income	208	283	1.615	1.318
Other expense	4	-2	2	-147
<b>Operating profit</b>	<b>-4.774</b>	<b>7.855</b>	<b>-4.044</b>	<b>17.380</b>
Net Financials	-358	-307	-1.056	-1.105
Foreign exchange adjustments	-	-	-	-
<b>Profit before tax</b>	<b>-5.132</b>	<b>7.548</b>	<b>-5.100</b>	<b>16.275</b>
Tax on profit for the year	789	-1.757	765	-2.382
<b>Profit for the period</b>	<b>-4.343</b>	<b>5.792</b>	<b>-4.335</b>	<b>13.893</b>


  

EUR '000	Q4 2020	Q4 2019	2020	2019
Depreciations included in production cost	-956	-1.628	-3.182	-3.895
<b>EBITDA</b>	<b>-3.818</b>	<b>9.483</b>	<b>-862</b>	<b>21.275</b>
<i>EBITDA fixed herd prices</i>	<i>-880</i>	<i>6.180</i>	<i>10.408</i>	<i>13.381</i>

Lithuania accounted for 55 % of Group revenue in Q4 2020 (Q4 2019: 63 %).

The EBITDA fixed herd price for Q4 2020 amounted to -880 kEUR, corresponding to an EBITDA margin of -7.1% (Q4 2019: 6,180 kEUR and EBITDA margin 32.0 %). The EBITDA decreased compared to Q4 2019 by 7.060 kEUR. The EBITDA is influenced by negative development in sales prices of 7,239 kEUR.

The sales price decreased 39 % compared to Q4 2019 to an average of 0,85 EUR per kilo slaughter pigs' live weight in Q4 2020 (Q4 2019: 1,39 EUR per kilo live weight slaughter pigs) with 7,239 kEUR negative effect.



## Russia

EUR '000	Q4 2020	Q4 2019	2020	2019
Revenue	10.157	11.573	41.203	45.488
Value adjustment, biological assets	-1.184	-707	2.006	-3.805
Production costs	-10.111	-12.057	-35.516	-38.828
Administrative costs	-170	-425	-1.038	-1.496
Other income	446	284	821	981
Other expense	-14	-43	-67	-109
<b>Operating profit</b>	<b>-875</b>	<b>-1.376</b>	<b>7.409</b>	<b>2.231</b>
Net Financials	-391	-258	-1.444	-1.532
Foreign exchange adjustments	101	-24	-128	-83
<b>Profit before tax</b>	<b>-1.166</b>	<b>-1.658</b>	<b>5.837</b>	<b>615</b>
Tax on profit for the year	-39	-255	-83	-256
<b>Profit for the period</b>	<b>-1.205</b>	<b>-1.913</b>	<b>5.754</b>	<b>359</b>


EUR '000	Q4 2020	Q4 2019	2020	2019
Depreciations included in production cost	-1.150	-1.241	-4.514	-4.598
<b>EBITDA</b>	<b>275</b>	<b>-135</b>	<b>11.923</b>	<b>6.829</b>
<i>EBITDA fixed herd prices</i>	<i>1.458</i>	<i>572</i>	<i>9.917</i>	<i>10.634</i>

Russia accounted for 45 % of Group revenue in Q4 2020 (Q4 2019: 37 %).

The EBITDA fixed herd price for Q4 2020 amounted to 1,458 kEUR, corresponding to an EBITDA margin of 14.4 % (Q3 2020: 572 kEUR and EBITDA margin 4.9 %), an increase of 886 kEUR.

Development in EBITDA split in different effects: Negative from sales price development 1.119 kEUR, a decrease of feed prices of 8% result in a positive impact of 567 kEUR and general cost reductions of 1.387 kEUR (partly due to RUB devaluation).

The sales price decreased 10 % compared to Q4 2019 to an average of 1,02 EUR per kilo slaughter pigs' live weight (Q4 2019: 1,13 EUR per kilo live weight slaughter pigs) with 1,119 kEUR negative effect.



## Statement by the Board and the Executive Management


The Executive Board and the Board of Directors have presented the interim Report of Idavang A/S. The interim Report has today been considered and adopted.


The Interim Report, which has not been audited or reviewed by the Company's independent auditors, was prepared in accordance with IAS 34 "Interim Financial Reporting" as adopted by the EU and additional Danish disclosure requirements for listed companies.

In our opinion, the Interim Financial Statements give a true and fair view of the financial position of the Group at 31st December 2020 as well as of the results of the Group operations and cash flows for the period 1st January – 31st December 2020.

Further, in our opinion, Management review gives a true and fair statement of the development of the group and parent company's activities and financial situation, net profit for the year and of the group and parent company's financial positions and describes the most significant risks and uncertainties pertaining to the group and parent company.

Executive Management

  
Claus Baltersen  
CEO

  
Michael Thuesen Henriksen  
CFO

Board of Directors

  
Niels Hermansen  
Chairman

  
Jytte Rosenmaj

  
Carsten Lund Thomsen

Claus Baltersen

  
Ole B. Hansen

## Financial Statement

### Income Statement

EUR '000	Q4 2020	Q4 2019	2020	2019
Revenue	22.471	30.900	101.754	110.540
Value adjustment, biological assets	-4.121	2.595	-9.264	4.089
Production costs	-23.953	-26.750	-88.616	-93.667
Administrative costs	-781	-1.442	-3.457	-4.586
Other income	654	566	2.436	2.305
Other expense	-10	-45	-72	-262
<b>Operating profit</b>	<b>-5.740</b>	<b>5.825</b>	<b>2.781</b>	<b>18.419</b>
Net Financials	-3.560	-1.605	-7.683	-6.563
Foreign exchange adjustments	506	167	-3.541	1.760
<b>Profit before tax</b>	<b>-8.794</b>	<b>4.388</b>	<b>-8.443</b>	<b>13.616</b>
Tax on profit for the year	750	-2.012	682	-2.638
<b>Profit for the period</b>	<b>-8.044</b>	<b>2.376</b>	<b>-7.761</b>	<b>10.979</b>

EUR '000	Q4 2020	Q4 2019	2020	2019
Depreciations included in production cost	-2.105	-2.873	-7.699	-8.498
<b>EBITDA</b>	<b>-3.635</b>	<b>8.698</b>	<b>10.480</b>	<b>26.917</b>
<i>EBITDA fixed herd prices</i>	<i>486</i>	<i>6.103</i>	<i>19.744</i>	<i>22.829</i>

### Statement of comprehensive income

EUR '000	Q4 2020	Q4 2019	2020	2019
Profit for the period	<b>-8.044</b>	<b>2.376</b>	<b>-7.761</b>	<b>10.979</b>
<b>Other comprehensive income</b>				
Exchange adjustments, foreign subsidiaries	1.474	487	-12.349	6.321
Hedge accounting	132	524	535	-352
<b>Other comprehensive income to be reclassified to profit or loss in subsequent periods</b>	<b>1.606</b>	<b>1.011</b>	<b>-11.814</b>	<b>5.969</b>
Other comprehensive income not to be reclassified to profit or loss in subsequent periods	-	-	-	-
<b>Total comprehensive income</b>	<b>-6.438</b>	<b>3.387</b>	<b>-19.575</b>	<b>16.948</b>

## Assets

EUR '000	Q4 2020	Q4 2019	2020	2019
Intangible assets	1.226	1.305	1.226	1.305
Property, Plant and Equipment	79.451	96.745	79.451	96.745
Biological Assets, Breeding herd	15.469	15.772	15.469	15.772
Deferred tax	760	757	760	757
Financial fixed assets	446	445	446	445
<b>Total non-current assets</b>	<b>97.353</b>	<b>115.024</b>	<b>97.353</b>	<b>115.024</b>
Inventories	12.195	15.599	12.195	15.599
Biological Assets, Commercial herd	17.116	27.662	17.116	27.662
Biological Assets, Arable	1.099	1.589	1.099	1.589
<b>Biological Assets</b>	<b>18.215</b>	<b>29.251</b>	<b>18.215</b>	<b>29.251</b>
Trade receivables	3.369	5.664	3.369	5.664
Other receivables	429	1.715	429	1.715
Prepayments	901	2.192	901	2.192
Income taxes receivables	-	351	-	351
<b>Receivables</b>	<b>4.699</b>	<b>9.922</b>	<b>4.699</b>	<b>9.922</b>
Assets held for sale	150		150	
Cash	13.757	30.286	13.757	30.286
<b>Total current assets</b>	<b>49.017</b>	<b>85.058</b>	<b>49.017</b>	<b>85.058</b>
<b>Total Assets</b>	<b>146.369</b>	<b>200.082</b>	<b>146.369</b>	<b>200.082</b>

## Liabilities and Equity

EUR '000	Q4 2020	Q4 2019	2020	2019
Share capital	800	1.000	800	1.000
Exchange adjustments	-38.577	-26.228	-38.577	-26.228
Other reserves	547	12	547	12
Retained earnings	67.098	92.564	67.098	92.564
<b>Equity</b>	<b>29.868</b>	<b>67.348</b>	<b>29.868</b>	<b>67.348</b>
Borrowings	80.282	92.735	80.282	92.735
Grants	1.598	2.003	1.598	2.003
Deferred tax	1.519	3.069	1.519	3.069
Provisions	-	134	-	134
Other non-current liabilities	39	39	39	39
<b>Non current liabilities</b>	<b>83.437</b>	<b>97.980</b>	<b>83.437</b>	<b>97.980</b>
Borrowings	21.268	27.694	21.268	27.694
Trade payables	8.396	5.332	8.396	5.332
Income taxes payables	559	-	559	-
Other payables	2.841	1.727	2.841	1.727
<b>Current liabilities</b>	<b>33.064</b>	<b>34.753</b>	<b>33.064</b>	<b>34.753</b>
<b>Total liabilities</b>	<b>116.501</b>	<b>132.733</b>	<b>116.501</b>	<b>132.733</b>
<b>Total Equity and Liabilities</b>	<b>146.369</b>	<b>200.082</b>	<b>146.369</b>	<b>200.082</b>

## Cash Flow Statement

EUR '000	Q4 2020	Q4 2019	2020	2019
Operating profit/loss	- 5.740	5.826	2.782	18.420
Depreciation and amortisation	2.104	2.873	7.698	8.498
Profit from sale of tangible assets	- 18	- 29	- 18	- 29
Accrual of hedging accounting	132	524	535	- 352
Share-based payments	- 134	-	- 134	-
Value adjustment, biological assets	4.121	- 2.595	9.263	- 4.089
Adjustment for non-cash operating items	6.205	773	17.344	4.028
	465	6.599	20.126	22.448
Changes in inventories	1.179	- 1.185	862	- 4.390
Changes in receivables	- 2.226	- 2.913	4.661	- 4.299
Accrual for trade receivable	-	-	-	-
Changes in trade payables	223	- 3.195	4.036	- 3.289
Changes in other current liabilities	1.147	- 769	991	- 242
Additions of biological assets	7	1.387	- 2.078	- 393
Change in working capital incl. herd	330	- 6.676	8.472	- 12.613
<b>Cash flow from ordinary activities before financials</b>	795	- 77	28.598	9.835
Net financials	- 2.784	- 1.118	- 6.869	- 6.076
Corporate tax paid	- 76	- 1.422	39	- 1.049
<b>Cash flow from ordinary activities</b>	- 2.065	- 2.616	21.768	2.710
<b>Cash flow from investing activities</b>	- 1.466	- 4.350	- 4.217	- 9.593
Proceeds from borrowings	81.290	18.500	88.578	18.500
Repayments of borrowings	- 78.646	- 9.719	- 101.296	- 21.269
Dividends paid to shareholders	-	-	-	-
Surplus on Escrow account	6.722	-	6.722	-
<b>Cash flow from financing activities</b>	9.366	8.781	- 5.996	- 2.769
Cash and cash equivalents primo priod	9.094	3.227	5.524	13.586
Change in cash and cash equivalents	5.834	1.814	11.555	- 9.652
Exchange adjustments	- 1.172	482	- 3.322	1.590
<b>Cash and cash equivalents end priod</b>	13.757	5.524	13.757	5.524

The group furthermore has 4.900 kEUR overdraft facilities not utilized at period-end and own 0 kEUR Idavang Bonds.

## Statement of changes in equity

EUR '000	Share capital	Exchange adjustment	Other reserves	Retained earnings	Total
Equity at 1st January 2020	1.000	- 26.228	12	92.564	67.348
Profit/Loss for the period				- 7.761	- 7.761
Other comprehensive income		- 12.349	535		- 11.814
Total comprehensive income	-	- 12.349	535	- 7.761	- 19.575
Dividend					-
Repurchase shares	- 200			- 17.705	- 17.905
Equity at 30th September 2020	800	- 38.577	547	67.098	29.868

EUR '000	Share capital	Share premium	Exchange adjustment	Other reserves	Retained earnings	Total
Equity at 1st January 2019	1.000	-	- 32.549	364	81.585	50.400
Profit/Loss for the period					10.979	10.979
Other comprehensive income			6.321	- 352		5.969
Total comprehensive income	-	-	6.321	- 352	10.979	16.948
Dividend						-
Transfer		-				-
Equity at 31st December 2019	1.000	-	- 26.228	12	92.564	67.348

## Notes

### Note 1 Basis of preparation and changes to the Group's accounting policies

The interim condensed consolidated financial statements for the 9 months ended 31st December 2020 have been prepared in accordance with Idavang A/S' accounting policies as stated in the latest financial statements for the company and in accordance with IAS 34 "Interim Financial Reporting" as adopted by the EU and additional Danish disclosure requirements for interim financial reporting of listed companies.

The consolidated financial statements are presented in thousand EUR.

The Interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual financial statements as at 31st December 2019.

The Group's accounting policies is unchanged compared with the Group's annual financial statements as at 31st December 2019.

### Note 2 Biological assets measured at fair value

The change in the value of biological assets for Q4 2020 is stated in the below table. The total change in fair value is included in revenue reported in the income statement.

EUR '000	Q4 2020	Q4 2019	2020	2019
<b>Commercial herd primo</b>	20.165	26.939	27.662	21.739
Change in fair value	-3.442	811	-8.197	4.523
Exchange adjustments	393	-88	-2.349	1.400
<b>Commercial herd ultimo</b>	<b>17.116</b>	<b>27.662</b>	<b>17.116</b>	<b>27.662</b>
<b>Breeding herd primo</b>	16.033	14.429	15.772	14.194
Change in fair value	-845	1.218	1.551	637
Exchange adjustments	281	125	-1.854	941
<b>Breeding herd ultimo</b>	<b>15.469</b>	<b>15.772</b>	<b>15.469</b>	<b>15.772</b>
<b>Herd total primo</b>	36.198	41.368	43.434	35.933
Change in fair value due to volume	-167	1.584	2.617	1.071
Change in fair value due to price	-4.121	445	-9.263	4.089
Exchange adjustments	675	37	-4.203	2.341
<b>Herd total ultimo</b>	<b>32.585</b>	<b>43.434</b>	<b>32.585</b>	<b>43.434</b>
<b>Crop primo</b>	611	1.589	1.589	1.453
Change in fair value due to volume	480	-128	-128	-73
Change in fair value due to price	-	-	-	-
Exchange adjustments	9	20	-362	209
<b>Crop ultimo</b>	<b>1.099</b>	<b>1.481</b>	<b>1.099</b>	<b>1.589</b>
<b>Total Biological Assets primo</b>	36.809	42.957	45.023	37.386
Change in fair value due to volume	313	1.456	2.489	998
Change in fair value due to price	-4.121	445	-9.263	4.089
Exchange adjustments	684	57	-4.565	2.550
<b>Total Biological Assets ultimo</b>	<b>33.684</b>	<b>44.915</b>	<b>33.684</b>	<b>45.023</b>

## Note 3 Segment reporting

The group's results break down as follows on segments:

Q4 2020					
EUR '000	Lithuania	Russia	Other / Eliminations		Group
Revenue	12.314	10.157	-		22.471
Value adjustment, biological assets	- 2.938	- 1.184	-		- 4.121
Production costs	- 13.843	- 10.111	2		- 23.953
Administrative costs	- 519	- 170	- 92		- 781
Other income	208	446	-		654
Other expense	4	- 14	-		- 10
<b>Operating profit</b>	<b>- 4.774</b>	<b>- 875</b>	<b>- 91</b>		<b>- 5.740</b>
Net Financials	- 358	- 391	- 2.811		- 3.560
Foreign exchange adjustments	-	101	405		506
<b>Profit before tax</b>	<b>- 5.132</b>	<b>- 1.166</b>	<b>- 2.496</b>		<b>- 8.794</b>
Tax on profit for the year	789	- 39	-		750
<b>Profit for the period</b>	<b>- 4.343</b>	<b>- 1.205</b>	<b>- 2.496</b>		<b>- 8.044</b>
EUR '000					
Depreciations included in production cost	- 956	- 1.150	2		- 2.105
<b>EBITDA</b>	<b>- 3.818</b>	<b>275</b>	<b>- 92</b>		<b>- 3.635</b>
<i>EBITDA fixed herd prices</i>	<i>- 880</i>	<i>1.458</i>	<i>- 92</i>		<i>486</i>
Q4 2019					
EUR '000	Lithuania	Russia	Other / Eliminations		Group
Revenue	19.327	11.573	-		30.900
Value adjustment, biological assets	3.302	- 707	-		2.595
Production costs	- 14.688	- 12.057	- 5		- 26.750
Administrative costs	- 368	- 425	- 649		- 1.442
Other income	283	284	-		566
Other expense	- 2	- 43	-		- 45
<b>Operating profit</b>	<b>7.855</b>	<b>- 1.376</b>	<b>- 654</b>		<b>5.825</b>
Net Financials	- 307	- 258	- 1.040		- 1.605
Foreign exchange adjustments	-	24	192		167
<b>Profit before tax</b>	<b>7.548</b>	<b>- 1.658</b>	<b>- 1.502</b>		<b>4.388</b>
Tax on profit for the year	- 1.757	- 255	-		- 2.012
<b>Profit for the period</b>	<b>5.792</b>	<b>- 1.913</b>	<b>- 1.502</b>		<b>2.376</b>
EUR '000					
Depreciations included in production cost	- 1.628	- 1.241	- 5		- 2.873
<b>EBITDA</b>	<b>9.483</b>	<b>135</b>	<b>- 649</b>		<b>8.698</b>
<i>EBITDA fixed herd prices</i>	<i>6.180</i>	<i>572</i>	<i>- 649</i>		<i>6.103</i>

2020					
EUR '000	Lithuania	Russia	Other / Eliminations		Group
Revenue	60.551	41.203	-		101.754
Value adjustment, biological assets	- 11.270	2.006	-		- 9.264
Production costs	- 53.098	- 35.516	- 2		- 88.616
Administrative costs	- 1.844	- 1.038	- 574		- 3.457
Other income	1.615	821	-		2.436
Other expense	2	- 67	- 7		- 72
<b>Operating profit</b>	<b>- 4.044</b>	<b>7.409</b>	<b>- 584</b>		<b>2.781</b>
Net Financials	- 1.056	- 1.444	- 5.183		- 7.683
Foreign exchange adjustments	-	- 128	- 3.413		- 3.541
<b>Profit before tax</b>	<b>- 5.100</b>	<b>5.837</b>	<b>- 9.180</b>		<b>- 8.443</b>
Tax on profit for the year	765	- 83	-		682
<b>Profit for the period</b>	<b>- 4.335</b>	<b>5.754</b>	<b>- 9.180</b>		<b>- 7.761</b>
EUR '000					
Depreciations included in production cost	- 3.182	- 4.514	- 2		- 7.699
<b>EBITDA</b>	<b>- 862</b>	<b>11.923</b>	<b>- 581</b>		<b>10.480</b>
<i>EBITDA fixed herd prices</i>	<i>10.408</i>	<i>9.917</i>	<i>- 581</i>		<i>19.744</i>
2019					
EUR '000	Lithuania	Russia	Other / Eliminations		Group
Revenue	65.052	45.488	-		110.540
Value adjustment, biological assets	7.894	- 3.805	-		4.089
Production costs	- 54.833	- 38.828	- 5		- 93.667
Administrative costs	- 1.904	- 1.496	- 1.186		- 4.586
Other income	1.318	981	-		2.299
Other expense	- 147	- 109	-		- 256
<b>Operating profit</b>	<b>17.380</b>	<b>2.231</b>	<b>- 1.192</b>		<b>18.419</b>
Net Financials	- 1.105	- 1.532	- 3.926		- 6.563
Foreign exchange adjustments	-	- 83	- 1.844		- 1.760
<b>Profit before tax</b>	<b>16.275</b>	<b>615</b>	<b>- 3.274</b>		<b>13.616</b>
Tax on profit for the year	- 2.382	- 256	-		- 2.638
<b>Profit for the period</b>	<b>13.893</b>	<b>359</b>	<b>- 3.274</b>		<b>10.979</b>
EUR '000					
Depreciations included in production cost	- 3.895	- 4.598	- 5		- 8.498
<b>EBITDA</b>	<b>21.275</b>	<b>6.829</b>	<b>- 1.187</b>		<b>26.917</b>
<i>EBITDA fixed herd prices</i>	<i>13.381</i>	<i>10.634</i>	<i>- 1.187</i>		<i>22.829</i>

#### Note 4 Summary of bond terms

<b>Issuer</b>	Idavang A/S
<b>Security package:</b>	(i) share pledges over Guarantors and Russian operating companies, (ii) mortgages over substantially Lithuanian real estate, (iii) Danish registered negative pledges, (iv) account pledge over IFC Deposit account and (v) assignment over intra-group loan (RUB 0.91bn) from the Issuer to Idavang Agro LLC
<b>Original Guarantors:</b>	Rus Invest Aps, Rurik A/S, Pskov Invest Aps, Idavang Russia A/S, UAB Idavang
<b>Status of the bond:</b>	Senior secured
<b>Currency:</b>	EUR
<b>Initial debt amount:</b>	EUR 75 millions
<b>Other facilities:</b>	Super senior RCF up to 9 mEUR, governed under an inter-creditor
<b>Tenor</b>	5 years
<b>Pricing:</b>	3m EURIBOR + 725 bps p.a., quarterly interest payments, EURIBOR floor of 0.0%
<b>Rating:</b>	Unrated
<b>Call options:</b>	Non call during the first 30 months, then 50/33/25/10/0 after 30/36/42/48/57
<b>Incurrence test</b>	Cash sweep of 50% of Free cash flow at 102.3925, starting from 2021
<b>Restricted payments</b>	NIBD/EBITDA LTM fixed herd price (net leverage) of 3.00 and No No financial support (by way of loans, capital or similar) by the Issuer to Russian subsidiaries, except if funded by the super senior facility or if the incurrence test is met (excluding the IFC Deposit from Net Interest Bearing Debt)
<b>Information covenants:</b>	Annual audited statements, quarterly unaudited reports
<b>Change of control:</b>	Investor put at 101%
<b>Listing of bonds:</b>	Nasdaq Copenhagen
<b>Trustee:</b>	Nordic Trustee
<b>Governing law:</b>	Danish law

## Quarterly Financial Highlights and Key Ratios

EUR '000	Q4 2020	Q3 2020	Q2 2020	Q1 2020	Q4 2019	Q3 2019
<b>Income statement</b>						
Revenue	22.471	24.728	25.826	28.730	30.900	29.161
EBITDA	- 3.635	3.432	- 2.666	13.349	8.699	6.117
EBITDA fixed herd price	486	7.253	4.754	7.250	6.104	9.052
EBIT	- 5.740	1.648	- 4.546	11.420	5.825	4.380
Financial items, net	- 3.054	- 3.628	- 387	- 4.156	- 1.437	- 1.362
Profit/(loss) for the period	- 8.044	- 1.477	- 4.728	6.487	2.376	2.611
<b>Cash flow</b>						
Operating activity	- 2.065	3.120	7.236	13.477	- 2.616	3.889
Investing activity	- 1.466	- 739	- 1.104	- 908	- 4.350	- 3.395
Financing activity	9.366	- 1.504	- 7.450	- 6.407	8.781	- 4.871
Free cash flow	- 748	3.771	7.695	13.702	- 5.849	2.294
<b>Balance sheet</b>						
Non-current assets	97.353	97.979	106.656	103.089	115.024	110.044
Net working capital	11.079	11.883	20.567	28.609	32.075	23.154
Net operating assets	108.432	109.862	127.224	131.698	147.099	133.198
Total assets	146.369	167.393	182.406	187.883	200.082	187.398
Equity	29.867	54.211	63.346	63.681	67.348	63.960
Net interest bearing debt	87.346	63.995	68.340	73.494	90.143	80.155
<b>Key financials Group</b>						
EBITDA margin	-16,2%	13,9%	-10,3%	46,5%	28,2%	21,0%
EBITDA margin - fixed herd prices	2,2%	29,3%	18,4%	25,2%	19,8%	31,0%
Cash conversion	-153,8%	52,0%	161,9%	189,0%	-95,8%	25,3%
NIBD / EBITDA fixed price LTM	4,4	2,5	2,5	2,5	3,9	4,3
Equity ratio	20,4%	32,4%	34,7%	33,9%	33,7%	34,1%

## Appendix / Production information

### Idavang Group

	Q4 2020	Q3 2020	Q2 2020	Q1 2020	Q4 2019	Q3 2019
<b>Number of Sows</b>						
Lithuania	15.344	15.170	15.125	14.981	15.048	15.293
Russia	10.335	10.410	10.474	10.261	10.257	10.184
Total	25.679	25.580	25.599	25.242	25.305	25.477
<b>Pigs sold (slaughterpigs, Weaners and Sows)</b>						
Lithuania	125.688	113.213	118.357	113.624	123.838	119.249
Russia	85.836	81.760	79.440	83.908	93.494	87.340
Total	211.524	194.973	197.797	197.532	217.332	206.589
<b>Displacement</b>						
Lithuania	- 4.177	7.784	3.101	2.144	- 4.389	- 1.195
Russia	- 472	5.427	10.254	1.181	- 5.792	4.005
Total	- 4.649	13.211	13.355	3.325	- 10.181	2.810
<b>Total production</b>						
Lithuania	121.511	120.997	121.458	115.768	119.449	118.054
Russia	85.364	87.187	89.694	85.089	87.702	91.345
Total	206.875	208.184	211.152	200.857	207.151	209.399
<b>Feed cost kEUR</b>						
Lithuania	- 8.952	- 9.118	- 8.952	- 8.706	- 8.659	- 9.034
Russia	- 6.934	- 6.600	- 6.597	- 6.698	- 7.027	- 7.528
Total	- 15.886	- 15.718	- 15.549	- 15.403	- 15.687	- 16.562
<b>Feed conversion kg/kg</b>						
Lithuania	2,78	2,83	2,81	2,85	2,84	2,91
Russia	2,96	2,85	2,91	2,86	2,87	2,92
Group	2,86	2,84	2,85	2,85	2,85	2,91